Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | IGF1R | P08069 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22804323 | 0.85 | HTR2A (0.53) | KDM4EHRH3 | |
| SCHEMBL19770184 | 0.84 | ACHE (0.62) | KDM4ESIGMAR1 | |
| SCHEMBL7651915 | 0.84 | ACHE (0.62) | KDM4ESIGMAR1 | |
| SCHEMBL30560122 | 0.82 | HTR2A (0.42) | KDM4EALDH1A1SIGMAR1 | |
| SCHEMBL12538992 | 0.79 | ACHE (0.55) | KDM4EALDH1A1 | |
| SCHEMBL4592063 | 0.79 | ALDH1A1 (0.54) | KDM4EALDH1A1SIGMAR1HRH3TNIK | |
| SCHEMBL1927705 | 0.78 | ALDH1A1 (0.58) | KDM4EALDH1A1POLBSIGMAR1HRH3 | |
| SCHEMBL4591942 | 0.76 | KDM4E (0.59) | KDM4EALDH1A1SIGMAR1HRH3 | |
| SCHEMBL22804380 | 0.76 | ACHE (0.55) | KDM4EALDH1A1SIGMAR1HRH3TNIK | |
| SCHEMBL29586876 | 0.76 | KDM4E (0.58) | KDM4EALDH1A1SIGMAR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018154-A1 | NEW INDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018154-A1 | NEW INDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2024-01-18 | — | — | US | disclosed |
| WO-2022117487-A1 | NEW INDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2022-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018154-A1 | NEW INDAZOLE DERIVATIVES | CYP3A43, CYP3A4, CYP3A5 | KDM4E 2371/4885ALDH1A1 364/4885POLB 4605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.